![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Boehringer Ingelheim Pharmaceuticals |
---|---|
Information provided by: | Boehringer Ingelheim Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00615992 |
The primary goal of this PMS study is to document the efficacy of Spiriva to improve physical activity measured by a score that is recommended in national COPD guidelines for monitoring the course of the disease.
Condition | Intervention | Phase |
---|---|---|
COPD |
Drug: Tiotropium |
Phase IV |
Study Type: | Observational |
Official Title: | Effect of Spiriva on the Activities of Daily Living Score Recommended in Austrian COPD Guidelines |
Estimated Enrollment: | 1000 |
Estimated Study Completion Date: | June 2008 |
Ages Eligible for Study: | 40 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
INCLUSION CRITERIA:
EXCLUSION CRITERIA:
Study Chair: | Boehringer Ingelheim Study Coordinator | BI Austria GesmbH |
Study ID Numbers: | 205.398 |
Study First Received: | January 24, 2008 |
Last Updated: | January 8, 2009 |
ClinicalTrials.gov Identifier: | NCT00615992 |
Health Authority: | Austria: Bundesamt fur Sicherheit im Gesundheitswesen, A-1030 Vienna |
Lung Diseases, Obstructive Respiratory Tract Diseases Lung Diseases Tiotropium Pulmonary Disease, Chronic Obstructive |
Parasympatholytics Respiratory System Agents Neurotransmitter Agents Cholinergic Antagonists Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Asthmatic Agents |
Cholinergic Agents Pharmacologic Actions Autonomic Agents Therapeutic Uses Peripheral Nervous System Agents Bronchodilator Agents |